Objects To analyze the expression of somatostatin receptor（SSTR）-2/5 in HBV-relatedhepatocellular carcinomas（HCC）and compare its clinicopathological features and follow-up data. Methods 22patients diagnosed with HCC between February 2008 and July 2010 underwent radical liver resection. Expression ofSSTR-2/5 in HCC and adjacent cirrhotic tissues were examined by immunohistochemistry and real time polymerasechain reaction（PCR）. Moreover，the relationship between SSTR expression and clinicopathological features werealso compared. The patients had routine follow-up exams until cancer reoccurred. Results Adjacent cirrhoticliver and HCC expressed SSTR-2/5. Compared to adjacent cirrhotic liver tissues，expression of SSTR-2/5 in tumorswere significantly lower〔SSTR-2 mRNA（RQ）：1.89±0.74 vs. 2.54±0.80，SSTR-5 mRNA（RQ）：3.61±1.66vs. 6.78±4.27 ；SSTR-2 protein ：68.2%（12/22）vs. 95.5%（21/22），SSTR-2/5 protein ：both 95.5%（21/22），all P＜0.05〕. The mean progression free survival for all patients was 27.3 months. The high SSTR-2/5 expressiongroup had significantly improved the progression free survival compared to the low expression group（log-rank＝4.08，P＝0.043）. Conclusions Down regulation of SSTR transcription may result in loss of a tumor suppressive.Characterization of SSTR expression can be used as a useful parameter to evaluate the prognosis of HCC.

Hepatocellular carcinomas, Somatostatin receptor, Prognosis

目的 观察生长抑素受体（SSTR）-2/5 在人原发性肝细胞肝癌及癌旁组织的表达，探讨其临床意义。方法 选择 2008 年 2 月至 2010 年 7 月期间在天津市第一中心医院住院手术治疗的 22 例肝细胞肝癌患者，切取病理组织，采用免疫组化和实时荧光定量聚合酶链反应（PCR）方法检测 SSTR-2/5 在肝癌及癌旁组织中的表达，并比较其与临床病理参数的关系。结果 癌旁组织和肝癌组织中 SSTR-2/5 均呈阳性表达 ；肝癌组织 SSTR-2/5 表达明显低于癌旁肝硬化组织〔SSTR-2 mRNA（RQ 值）：1.89±0.74 比2.54±0.80，SSTR-5 mRNA（RQ 值）：3.61±1.66 比 6.78±4.27；SSTR-2蛋白：68.2%（12/22）比 95.5%（21/22），SSTR-2/5 蛋白均为 95.5%（21/22）；均 P＜0.05〕。全部患者术后平均无瘤生存期为 27.3 个月，SSTR-2/5 高表达组较低表达组无瘤生存期延长（log-rank＝4.08，P=0.043）。结论 SSTR 低表达预后相对较差，SSTR表达的表征可以被用来作为评估肝癌预后的有用参数。

肝细胞肝癌 , 生长抑素受体 , 预后